Oragenics Inc. (OGEN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OGEN SEC filings page.
This page shows Oragenics Inc. (OGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures describe a research-led company financed by new capital, with cash use still closely tracking operating losses.
In FY2025, operating cash flow of-$9.2M nearly matched operating income of-$9.4M , indicating that reported losses largely reflected ongoing cash-consuming operations rather than a large working-capital distortion. At the same time, financing cash flow of$16.8M exceeded that operating use, making external funding the main source of balance-sheet improvement.
Capital structure changed sharply: equity moved from negative
The spending mix shifted toward overhead: R&D fell from
Financial Health Signals
Oragenics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Oragenics Inc. reported an operating loss of $9.4M against $786K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Oragenics Inc. reported -$2.5M in net income in Q2 2026. This represents a decrease of 11.3% from the same quarter a year earlier. Against the prior quarter it is down 14.9%.
Oragenics Inc. earned -$0.57 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 11.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Oragenics Inc. held $3.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Oragenics Inc.'s ROE was -68.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 33.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Oragenics Inc. invested $1.2M in research and development in Q2 2026. This represents an increase of 161.7% from the same quarter a year earlier. Against the prior quarter it is up 82.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
OGEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.2M+161.7% | $645K+89.0% | N/A | $931K+5.9% | $450K-50.4% | $342K-48.5% | N/A | $879K+14.3% |
| SG&A Expenses | $1.4M+12.0% | $1.6M-4.4% | N/A | $2.2M+40.7% | $1.3M-9.6% | $1.7M-6.2% | N/A | $1.6M+16.9% |
| Operating Income | -$2.6M-51.2% | -$2.3M-11.3% | N/A | -$3.1M-28.2% | -$1.7M+25.7% | -$2.0M+17.6% | N/A | -$2.4M-16.4% |
| Interest Expense | $414-99.9% | $4K-98.1% | N/A | $7K-29.4% | $572K+31642.1% | $199K+2710.5% | N/A | $10K-29.6% |
| Income Tax | -$46K | -$23K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.5M-11.3% | -$2.2M+0.7% | N/A | -$3.1M-24.5% | -$2.3M+1.4% | -$2.2M+9.5% | N/A | -$2.5M-22.4% |
| EPS (Basic) | -$0.57+81.6% | -$0.51+86.0% | $0.60+645.5% | -$1.96+82.7% | -$3.10+79.7% | -$3.65-421.4% | -$0.11+98.0% | -$11.32-1231.8% |
| EPS (Diluted) | -$0.57 | -$0.51 | $0.60 | -$1.96 | -$3.10 | -$3.65 | -$0.11 | -$11.32 |
| Diluted Shares (Avg) | 4M | 4M | N/A | 2M | 731,817 | 607,208 | N/A | 217,602 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA.
OGEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.5M+156.7% | $7.5M+93.6% | $10.1M+583.7% | $12.7M+144.1% | $2.1M-21.0% | $3.9M+9.5% | $1.5M-70.4% | $5.2M-34.1% |
| Current Assets | $5.5M+156.7% | $7.5M+93.6% | $10.1M+583.7% | $12.7M+208.9% | $2.1M+32.2% | $3.9M+58.4% | $1.5M-61.9% | $4.1M-47.4% |
| Cash & Equivalents | $3.9M+95.8% | $6.1M+78.5% | $4.4M+408.7% | $11.4M+262.7% | $2.0M+46.4% | $3.4M+65.1% | $865K-75.2% | $3.1M-45.5% |
| Short-Term Investments | $0 | $0 | $4.0M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.8M-57.3% | $1.3M-64.9% | $1.8M+6.1% | $2.9M+35.2% | $4.3M+208.5% | $3.7M+310.6% | $1.7M-6.3% | $2.1M+51.7% |
| Total Equity | $3.7M+272.5% | $6.2M+4389.7% | $8.3M+4008.4% | $9.8M+219.5% | -$2.1M-260.4% | $138K-94.8% | -$212K-106.7% | $3.1M-52.6% |
| Retained Earnings | -$231.4M-4.6% | -$228.8M-4.5% | -$226.6M-4.5% | -$224.3M-5.1% | -$221.3M-4.9% | -$219.0M-5.0% | -$216.8M-5.1% | -$213.4M-10.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.
OGEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.2M-66.4% | -$2.2M-4.2% | -$2.8M-40.5% | -$3.0M-51.5% | -$1.3M+14.9% | -$2.1M+31.1% | -$2.0M-83.1% | -$2.0M-31.1% |
| Stock-Based Compensation | N/A | $17K-1.8% | N/A | N/A | N/A | $18K-74.5% | N/A | $331K+18.6% |
| Investing Cash Flow | $0 | $4.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$56K+57.8% | -$92K-102.0% | -$169K+35.4% | $12.4M+229.7% | -$133K-116.2% | $4.7M+182.5% | -$261K-44.4% | $3.8M+414.4% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
OGEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -68.9% | -35.6%+1574.6pp | N/A | -31.2%+48.8pp | N/A | -1610.2%-1516.8pp | N/A | -80.0%-49.0pp |
| Return on Assets | -46.0%+60.1pp | -29.4%+27.9pp | N/A | -24.1%+23.2pp | -106.2%-21.1pp | -57.3%+12.1pp | N/A | -47.3%-21.8pp |
| Debt-to-Equity | 0.50 | 0.21-26.9x | 0.22 | 0.29-0.4x | N/A | 27.10+26.8x | N/A | 0.69+0.5x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Oragenics Inc. OGEN | FY2025 | N/A | N/A | N/A | $2.0M | — |
| Xenetic Biosciences, Inc. XBIO | FY2025 | $3.0M | -$2.7M | -90.1% | $5.0M | 66/100 |
| GRI Bio, Inc. GRI | FY2025 | N/A | -$12.0M | N/A | $3.4M | — |
| Aptevo Therapeutics Inc APVO | FY2025 | N/A | -$26.0M | N/A | $3.3M | — |
| Onconetix, Inc. ONCO | FY2025 | $815K | -$14.0M | N/A | $3.1M | — |
| Quoin Pharmaceuticals, Ltd. QNRX | FY2025 | N/A | -$15.8M | N/A | $8.8M | — |
Where Oragenics Inc. Ranks
Frequently Asked Questions
What is Oragenics Inc.'s operating cash flow?
Oragenics Inc. (OGEN) recorded an outflow of $9.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oragenics Inc.'s total assets?
Oragenics Inc. (OGEN) had $10.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Oragenics Inc. spend on research and development?
Oragenics Inc. (OGEN) invested $2.4M in research and development during fiscal year 2025.
What is Oragenics Inc.'s debt-to-equity ratio?
Oragenics Inc. (OGEN) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oragenics Inc.'s P/E ratio?
Oragenics Inc. (OGEN) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $2.0M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Oragenics Inc.'s price-to-sales ratio?
Oragenics Inc. (OGEN) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.0M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Oragenics Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Oragenics Inc. (OGEN) held $8.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.2M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Can Oragenics Inc. cover its interest payments?
Oragenics Inc. (OGEN) reported an operating loss of $9.4M against $786K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.